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Abstract  
Context.  The challenges of palliative care clinical trial recruitment are well documented. 
Objectives. To review tested strategies to improve recruitment to trials of people with a 
range of conditions who may access palliative care services but are not explicitly stated to be 
"palliative."  
Methods.  This was a systematic review with narrative description. The Cochrane, 
Embase, PubMed, PsycINFO and CINAHL electronic databases were searched (English; Jan. 
2002-Feb. 2014) for quasi-experimental and randomized controlled trials (RCTs) testing the 
effect of recruitment strategies on accrual to clinical trials of people with organ failure and 
cancer. Titles, abstracts and retrieved papers were screened by two researchers and categorized 
by recruitment challenge:1) patients with reduced cognition, 2) those requiring emergency 
treatment, and 3) willingness of patients and clinical staff to contribute to trials. 
Results. Of 549 papers identified, 15 were included. Thirteen reported RCTs and two 
papers reported three quasi-experimental studies. Five were cluster RCTs of recruiting 
sites/institutions. One was a randomized cluster crossover feasibility study. Seven studies 
recruited patients with cancer. Others included patients with dementia, stroke, cardiovascular 
disease, diabetes, frail elderly and bereaved carers. Some interventions improved recruitment: 
memory aid, contact prior to arrival, cluster consent, "opt out" consent. Others either reduced 
recruitment (formal mental capacity assessment; a variety of educational, supportive and 
advertising interventions) or made no difference (advance research directive). 
Conclusion. Successful strategies from other disciplines could be considered by 
palliative care researchers. Tailored, efficient, evidence-based strategies must be developed, 
acknowledging that strategies with face validity are not necessarily the most effective.  
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Introduction 
The challenges faced when recruiting participants into palliative care trials are cited as 
the reason for poor accrual, resulting in abandoned or underpowered studies (1-4). This 
represents a poor return for the time and effort of the participants and the funding bodies, and 
fails to address the need for interventions to have high-level evidence to support their use in the 
palliative care population, with regard to efficacy, safety and tolerability (5, 6). 
The difficulties of recruitment to clinical trials in palliative care have been well 
documented (1-3, 7, 8). Mostly these center on ethical and logistical issues. Ethical issues relate 
to the burden and intrusiveness of study measures on the participants, concerns regarding 
randomization, and gate-keeping by clinicians, carers and Ethics Committees. Logistical issues 
include lack of research infrastructure such as trials unit support, research funding, collaborative 
centers, sponsorship, indemnity and research time, particularly for clinicians. Further, palliative 
care patients have an expected trajectory of deterioration and death that may complicate the 
ethical issues in this population, and increases the risk of underpowered trials (9). 
The remit of palliative care is evolving to include people with non-cancer conditions. 
Despite similar recruitment challenges, clinical trials have been successfully completed in this 
population even with advanced disease (10). Indeed, some recruitment strategies (Table 1) have 
already been successfully applied in palliative care trials, increasing the number of adequately 
powered clinical trials of palliative care interventions (8, 11-14). 
As people with a range of conditions are increasingly cared for by palliative care 
services, recruitment strategies tested in such populations, which may not be explicitly named as 
“palliative care,” may provide useful information for palliative care researchers. Previous 
reviews have restricted the search to studies in explicitly palliative care populations or 
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conversely have reviewed an extensive range of conditions and study interventions, including 
public health interventions (1, 10, 15). For this review a “palliative care patient” is defined in 
terms of the health status (progressive, incurable illness) and the care given (multidisciplinary, 
holistic approach) (1, 16). 
The aims of this study were: 1) to identify, assess and summarize the findings of 
randomized or quasi-experimental trials of strategies designed to optimize trial recruitment of 
people with cancer or organ failure (including cognitive failure) compared with usual methods 
with regard to effect on trial accrual; and 2) to identify those strategies applicable to palliative 
care clinical studies. 
Methods 
Cochrane, Embase, PubMed, PsycINFO and CINAHL electronic databases were 
searched using terms developed from those used by Wohleber (7), Lovato (10), Rinck (15) and 
Sladek (17) (Table 2). These were extended to include other conditions mapped to medical 
subject heading (MeSH) terms. Search #17 had titles and abstracts reviewed for inclusion; 
eligibility criteria are shown in Table 3. Reference lists from identified reviews were hand-
searched. An initial search was performed in November 2012 and updated in February 2014. 
Inclusion Criteria 
Types of Participants. Studies of patients with cancer, or conditions affecting vital 
organ(s) including dementia, delirium and stroke were included. 
Types of Studies. Studies that tested the effect of a recruitment strategy on recruitment to 
a clinical study as a primary outcome a priori using a randomized or quasi-experimental design 
were included. Trials could randomize at individual patient or cluster level, and be phase 2 or 3. 
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Types of Interventions. Trials could test any recruitment strategy targeted at any step of 
the recruitment pathway (e.g., the different steps that could influence the participant being 
included in a study), and be directed at the individual patient, or recruiting site. 
Types of Outcomes. Measures of recruitment could include number/percentage of 
participants recruited, number of institutions recruiting, recruitment per center, and mental 
capacity to provide one’s own rather than proxy consent. 
Data Collection and Analysis 
Selection of Studies.  Two reviewers (J.B., M.J.) reviewed all titles and abstracts. Full 
papers were retrieved for those eligible, or indeterminable from titles and abstracts. Two 
reviewers (J.B., M.J.) assessed the full text of all potentially relevant studies. Disagreement was 
resolved by consensus and with recourse to a third reviewer (A.W.). 
Data Extraction. Data were extracted (J.B., C.P.) using a data extraction form based on 
areas influencing study recruitment (7) (Appendix). Unreported data were not requested. 
Categorization of Studies.  Studies were categorized according to the stage of the 
recruitment process at which the recruitment strategy they used was directed. A grade of 
evidence using the Jadad score was assigned for the randomized controlled trials (RCTs). This 
score is based on the following five questions:  Was the study described as random, was the 
randomization scheme described and appropriate,  was the study described as double-blind, was 
the method of double blinding appropriate (i.e., were both the patient and the assessor 
appropriately blinded), and was there a description of dropouts and withdrawals? The maximum 
score is 5 (18). 
Analysis.  The key features of the included studies (design, patient population, 
recruitment strategy evaluated, study outcome and effect on recruitment) are presented in tables 
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and analyzed with narrative description. Because of the clinical and methodological 
heterogeneity, a meta-analysis was considered inappropriate. Data are presented according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
Results  
The search identified 549 studies of which 15 were eligible. The process of selection is 
shown in Fig. 1 and the studies are summarized in Table 4 (more detail in Table 4A, available at 
jpsmjournal.com). Table 5 lists the full-text articles that were retrieved but not included, with 
reasons for exclusion. 
Description of Studies 
Thirteen articles reported RCTs testing a recruitment strategy, with another two papers 
describing three quasi-experimental studies. Of the 13 RCTs, one was a three-arm parallel study, 
seven were two-arm parallel studies, five were cluster RCTs of potential recruiting 
sites/institutions, and one was a randomized cluster crossover feasibility study. In the individual 
patient randomized trials, the primary outcome was trial accrual, with one (19) focusing on 
whether the patient had the mental capacity to provide their own consent. The cluster trials all 
reported recruitment rate per site.  
Quality of Included Studies.  Only one study scored more than 3 of 5 on the Jadad scale.. 
Many of the studies lost two points because of lack of blinding, although this would have been 
difficult or impossible.  
Description of Participants/Institution Clusters 
Seven of the 15 studies recruited patients with cancer (20-26). The others included a 
range of participants who highlighted recruitment challenges associated with: reduced capacity 
to consent (two studies in dementia (19, 27), one in acutely unwell medical inpatients (28)); need 
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for urgent medical intervention (one in acute stroke (29)); and bereavement (one study of 
bereaved carers (30)). Two studies recruited people with cardiovascular disease (angina (31) and 
diabetic vascular disease (32)). The two quasi-experimental studies reported in one paper were of 
elderly community dwellers at risk of falling (33). Although not clearly in a study inclusion 
disease category, it was felt the studies were likely to include participants relevant to our 
question. Only one study included patients admitted to a palliative care unit (25). 
Description of Interventions 
The included studies targeted three specific challenges in recruitment: 
1) Potential Participants with Reduced Cognitive Ability. These studies investigated the 
use of a memory and organizational aid; a research advance directive; or an augmented 
assessment of mental capacity to consent. 
2) Potential Participants Requiring Emergency Treatment. One study used a method of 
advance information provision to specific potential participants. A cluster randomized trial of 
palliative care patients admitted for terminal care tested two methods of consent – either at a 
cluster level, or at the individual patient level.  
3) Effective Dissemination of rial Information and Raising Recruitment Willingness 
Among Potential Participants and Recruiting Site Staff. A variety of interventions were tested. 
Effect on Rcruitment Rate. 
1) Potential Participants with Reduced Cognitive Ability. A memory and organizational 
aid increased the number of participants with Alzheimer’s dementia (Mini-Mental State 
Examination 18-27) able to provide their own consent compared with standard consent 
procedures (46% vs. 33%; P = 0.004) (19) but the use of advance consent versus usual 
consenting practice, for research in people with dementia, and their family proxies, did not 
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improve trial recruitment (27). In the latter trial, 149 patients and family proxies provided a 
research advanced directive (Planning Ahead Together [PAT] document). Over the following 
two years, 41 patients were invited to participate in a study of whom 27 consented. There was no 
difference in consent rate between those with or without a PAT (23 PAT, 18 no PAT). 
In a study of acutely unwell medical in-patients (N = 130), participants were randomized 
to have a formal assessment of mental capacity prior to the usual informed consent procedure or 
to have a single step procedure. Those receiving a formal assessment of mental capacity were 
less likely to be judged competent to provide informed consent (60% vs. 86%; P = 0.001) and 
less likely to be randomized (44% vs. 74%) (28). Unsurprisingly, those randomized had less 
severe delirium than the comparator group, indicating that selection bias had occurred (28). 
A feasibility cluster trial assessed the effect of two levels of consent (at the cluster level 
[N = 24] or at an individual patient level using a Zelen design [N = 29]) for a trial of anti-emetics 
in patients admitted to a palliative care unit or oncology ward for terminal care (25). Using a 
Zelen design, participants are randomly allocated to either the intervention or control group prior 
to giving informed consent; participants randomized to receive the intervention are then 
approached, offered the intervention, which they can then decline or accept.  In the cluster group, 
13 patients consented of whom six were randomized, but in the Zelen group, only two were 
consented and none were randomized. Nursing staff were less willing to approach an individual 
patient for consent in the Zelen arm as it required consent for a change in treatment, whereas 
with a cluster design, the consent was only for a patient’s data to be used (25). 
2) Potential Participants Requiring Emergency Treatment.  The two studies discussed 
above (25, 28) were both conducted in patients who, in addition to fluctuating cognition, may 
also require emergency treatment. 
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A trial testing early patient/proxy contact to invite study participation by potential stroke 
patients (N = 100) while awaiting medical evacuation to a tertiary treatment center increased the 
consent rate to 68% compared with 50% in those approached only on arrival (29).  
3) Effective Dissemination of Trial Information and Raising Recruitment Willingness 
Among Potential Participants and Recruiting Site Staff.  
Potential Participants.  A cluster RCT comparing easy to read (N = 89) or standard 
consent information (N = 137) for a cancer trial did not influence either the decision to 
participate (82% vs. 89%; P = 0.21) or actual accrual rate (75% vs. 68%; P= 0.32) (20).  
An educational video about clinical trials for lung cancer patients (N = 63) did not statistically 
significantly increase enrolment rates over a control group (N = 63) for either therapeutic (18% 
vs. 11%; P = 0.3) or non-therapeutic trials (25% vs. 16%; P = 0.19) (22). Similarly, an RCT (N = 
196) of enrollment into therapeutic breast cancer trials was unaffected by the use of an 
educational video; 10% (video group) vs. 6%; P = 0.3) (23). The provision of audiovisual 
information in addition to standard trial specific information did not lead to an increased 
recruitment rate (72% [audiovisual group; N = 86] vs. 76% [N = 87]; odds ratio 1.19, 95% 
confidence interval 0.55, 2.58; P = 0.66) (21). Two quasi-experimental studies testing the effect 
of study specific newspaper articles in addition to standard participant information did not 
statistically significantly increase the recruitment rate to a falls prevention study in primary care 
in those over 70 years of age (study 1, N = 4488: 3% [newspaper article group] vs. 3%; study 2, 
N = 2745: 4% vs. 4%). 
Two studies tested an “opt out” versus “opt in” consent process. Junghans and colleagues 
randomized primary care patients with angina (n = 510) to have an “opt in” or “opt out” 
approach to recruitment in an observational study (31). The “opt out” group (n = 258) had a 
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higher recruitment rate (50% vs. 38%; P = 0.014). However, the “opt in” group who consented 
had fewer risk factors (P = 0.53), were on less treatment for angina (P = 0.01) and had less 
functional impairment (P = 0.02) than those in the “opt out” group. In a quasi-experimental 
study, bereaved carers (N = 1422) were contacted to take part in a survey and were allocated to 
an “opt in” or “opt out” response (30). Again, there was a higher response rate in the “opt out” 
group (40% vs. 26%; P< 0.01). 
Potential Recruiting Sites.  One cluster RCT allocated 53 institutions recruiting to cancer 
and leukemia trials to have extensive and time-consuming augmented information and support 
about ongoing trials targeted to increase recruitment of patients over 65 years of age (seminars, 
protocol lists, monthly reminders, case discussions) and 72 to have a standard approach only 
(website access and periodic notification of trials). The additional intervention did not improve 
the proportion of people over 65 recruited (proportion recruited at one year: 32% vs. 36%; P = 
0.35; at two years: 31% vs. 31%; P = 0.83) (26). Another trial compared face-to-face site visits 
(N =68) with none (N=67). Although there were more sites that were classified as “excellent 
recruiters” in the visited group, overall, there was no statistically significant advantage (302 
randomized patients in the visited group vs. 271 in the comparator group) (24). A third compared 
extensively augmented communication strategies from the co-ordinating trial center (85 sites) 
compared with usual strategies (82 sites). The augmented effort did not increase the median 
number of patients randomized by center during follow up (38 patients [augmented group] vs. 37 
patients [comparator group]; P = 0.68) (32). 
Discussion 
This review identified highly relevant lessons for palliative care researchers from trials 
conducted by other disciplines providing care for patients with advanced disease. These lessons 
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address specific clinical considerations relating to potential patient involvement as well as the 
approaches being tested to improve participation and retention.  The following discussion relates 
the findings to particular issues faced in palliative care studies. 
Potential Participants with Reduced Cognitive Ability 
Although, ethical procedures are agreed in most countries for proxy consent or consultee 
assent, strategies, such as a memory aid, which improve the opportunity for patients to provide 
their own consent are to be welcomed (19). However, formal assessment of mental capacity prior 
to consent reduced the patient-provided consent rate, and introduced selection bias (28). 
Delirium is common in palliative care patients. Prevalence estimates range from 13-42% 
on admission to a palliative care unit, increasing to 88% in the days before death (34). The 
consenting process can be burdensome, and required when mental capacity is reduced, or 
fluctuating, in a context of distress for the patient and family and increased gatekeeping among 
clinical staff and ethics committees (14, 35-38). Symptom management interventions for dying 
patients commonly have low level evidence partly because of challenges of consenting dying 
patients to clinical trials (5, 39). The ethical challenges of recruiting palliative care patients to 
clinical trials of delirium have been summarized well in a recent discussion paper (25), which 
highlighted the importance of memory and other aids to facilitate capacity (such as that used by 
Rubright et al.) (19, 40). Research into delirium in palliative care is an example of progress made 
despite the enormous challenges, and where study design and conduct has benefited from 
collaboration between palliative care and other disciplines (34, 41). 
The use of advance consent has been discussed, particularly in the field of dementia (42). 
However, in this review, the use of an advance research directive did not improve recruitment 
(27). This approach is possible in palliative care, as seen in an observational feasibility cohort 
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study of patients admitted for terminal care. Although half of those approached (N=107) 
provided advance consent (n=58), only 15 were randomized during eight months of follow up 
(43).  
Potential Participants Who Require Emergency Treatment 
Contact prior to arrival at the trial site increased consent rate to a stroke trial (29).  
Deferred consent is an accepted way of entering patients who cannot provide consent into 
emergency treatment trials (14, 44). Palliative care patients have fluctuating mental capacity and 
the challenge of requiring emergency management. However, the palliative care participant may 
not be expected to recover, and the issue then of whether their data can be used is unclear. Even 
where the patient has capacity, or a proxy is present, the urgent nature of the situation can make 
the recruiting process difficult. Therefore, contact prior to arrival at the trial site may be useful in 
palliative care trials. For example, as the use of telehealth increases in long-term conditions, this 
may help identify eligible trial participants who present as an emergency, and has been 
successfully used in another stroke study (45). 
Cluster consent designs, more commonly used in complex intervention trials, also may be 
useful in situations where clinical staff gatekeeping is a significant barrier even with simple 
interventions (25). Recruitment is also challenging where, despite genuine uncertainty and thus 
ethical equipoise, there is a wish (patient or clinician) to receive the study intervention. Study 
designs such as crossover trials are useful in this situation (46), but are not always possible. 
Other designs, e.g., “wait-list” design RCTs, have been used in the palliative care setting (47), to 
allow all participants to receive the study intervention, but have not been tested as a recruiting 
strategy.  
Strategies to Improve Trial Information and Research Willingness 
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 Potential Particiants.  The studies in this review that aimed to increase potential recruits’ 
willingness did not show accrual rate benefit despite the “face validity” of the interventions. 
Given the effort and logistics required to use these interventions in practice, it is important to 
know they were ineffective when subjected to formal testing.  
Efficient study-specific “advertising” strategies, therefore, should be developed and take 
into account knowledge of “patient flow” through the service at any recruiting site. For example, 
a study recruiting women with ischemic heart disease to a rehabilitation trial found that, despite a 
wide variety of invitation strategies, the majority (73%) were recruited via routine referral for 
cardiac rehabilitation (48). In another study of exercise in breast cancer survivors, potential 
participants were identified through a cancer registry and local media advertisements (49). Many 
responded through the cancer registry, but were less likely to consent compared with those who 
responded to advertisements. 
“Opt out” consent options increased recruitment in this review (30, 31). Although this 
method also has been noted to be effective in a Cochrane review of recruitment strategies tested 
in a broad range of studies, specific limitations need to be taken into account (50). 
Potential Recruiting Sites. Educational and other initiatives, again with face validity, to 
support recruiting site clinical staff were not effective in increasing site recruitment when 
formally tested.  
Gatekeeping may be by individuals, committees, or by institutions. Services may be 
organized leaving no space or time for patients to be approached, resulting in a culture whereby 
research is thought of as a burden, or not at all (7). In a palliative care prognostication study, 
gatekeeping by clinical staff accounted for 24% of inaccessibility (51). Thus, raising a trial’s 
profile and changing an institution’s culture are necessary. Contacts with the clinicians most 
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likely to refer eligible patients are often achieved through personal relationships (52). The 
importance of study-specific researchers is highlighted in a U.K. primary care study, where 
accrual was improved by study researchers being in direct contact with general practices, rather 
than depending on generic research network staff intervening between researchers and general 
practitioners (53).   
Limitations 
There are no unique search terms to identify palliative care studies, or those involving 
people with advanced disease. Therefore, it is likely that useful papers will have been 
overlooked. We have not entered into the debate about the definition of the “palliative care 
patient,” which we feel is beyond the scope of this paper.  
However, the aim of the review was to seek studies of recruitment strategies in 
populations that, although not explicitly stated to be “palliative,” would be informative to 
researchers in this field, rather than to gain exhaustive inclusion in order to complete an accurate 
meta-analysis of efficacy. Many of the studies varied in their standard of reporting (18). 
Although some study interventions would have been difficult or impossible to blind, two of the 
cluster RCTs only had a Jadad score of 1/5 as the method of randomization, withdrawals and 
dropouts was not described (20, 26). 
Implications for Future Research Practice 
These studies highlight options that could be considered and tested. Of particular note, 
many of these studies used well-defined strategies with good face validity but did not achieve the 
desired outcomes. Further research on recruitment would ensure that the work of researchers and 
the contributions of patients, their carers, and families are used to best effect.  
Conclusions 
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Palliative care trials do not have the monopoly on “difficult to recruit” participants and 
neither is clinician gatekeeping exclusively a problem in palliative care settings. Accrual to 
clinical trials is always challenging but clinical trials are crucially important to develop evidence- 
based management for our patient group, so we can stop “experimenting on our patients” and 
“settling for low level evidence” (5, 6). There are good examples where well-designed palliative 
care trials that include explicit and flexible recruitment strategies are completing AU: COMPLETING? 
to answer important clinical questions to inform daily practice (8, 12, 13). Palliative care 
researchers can learn from colleagues in different disciplines about how to overcome challenges 
of gatekeeping and consent in populations with reduced capacity requiring emergency treatment. 
Tailored and efficient evidence-based strategies to optimize recruitment must be developed for 
each study, learning the lesson that techniques that appeared to be appropriate and useful were 
not necessarily the most effective.  
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Table 1. Strategies Used in Successful Palliative Care Clinical Trials 
 
 
 
 
 
 
 
 
 
 
- realistic recruitment timescales 
- close monitoring of recruitment with regular adjustment of 
strategy as necessary 
- adequate dedicated research staff 
- multi-center 
- adequate trial unit infrastructure support 
- careful attention to the consenting process, study design, 
study duration and study assessment burden 
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Table 2. Search Strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limits: 
 
Date: 2002-2012 (#1 to #17);  
Language: English – all searches 
Study design: randomized or controlled clinical trials; therapy – all databases except 
Cochrane 
Methodological studies - Cochrane database search only 
Humans; adults – all searches 
 
Terms were mapped to MeSH headings and text word searches used the terms: 
‘‘Recruit*,’’ OR ‘‘Recruitment strategy,’’ OR ‘‘ethics research,’’ OR ‘‘Experimental 
ethics,’’ OR ‘‘informed consent,’’ OR ‘‘methodology,’’ OR ‘‘experimental subjects’’ 
“end stage”, OR ”advanced disease”, AND “lung”, OR “pulmonary”, OR “renal”, OR 
“heart”, OR “cardiac” OR “oncology” OR “cancer” 
 
Searches: 
#1 exp Patient, selection/ 
#2 exp Ethics, Research/ 
#3 exp Research subjects/ 
#4 exp Patient recruitment/ 
#5 #1 or #2 or #3 or #4 
#6 remove duplicates from#5 
#7 exp Lung/ 
#8 exp Kidney/ 
#9 exp Heart/ 
#10 exp Liver/ 
#11 exp Neoplasm/ 
#12 exp Dementia/ 
#13 exp Delirium 
#14 exp Stroke/ 
#15 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
#16 remove duplicates from#15 
#17 #6 and #16 
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Table 3. Study Inclusion/Exclusion Criteria 
 
 
Inclusion: 
- Population: adults with chronic organ failure (including cognitive), cancer 
- Design: Clinical studies – RCTs, quasi-experimental  
- Intervention: any recruitment strategy,  
- Language limits: English 
Exclusion:  
- Population: studies that only included people requiring proxy consent; children; 
general population (e.g., public health initiatives) 
- Design: systematic literature review, observational studies, qualitative pieces, 
opinion pieces, case histories 
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Table 4. Randomized Controlled Trials Evaluating Recruitment Strategies in Populations with Organ Failure or Cancer 
Thematic Grouping 
Study (Jadad 
score, RCTs) 
Target Population Intervention and Comparator  
Significantly 
Increased 
Recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
A
R
T
I
C
I
P
A
N
T
 
–
 
R
E
L
A
T
E
D
 
S
T
U
D
I
E
S
 Participants with 
decreased cognition 
Rubright 2010 
(3) Alzheimer’s dementia 
 
I: Memory / organizational aid 
C: Usual consent process 
Yes  
Stocking 2007 
(2) 
I: Research advance directive 
C: Usual consent process 
No 
Adamis 2005 
(3) 
Unwell inpatients >70yrs 
I: Formal assessment of mental 
capacity 
C: Usual consent process 
Noa 
Fowell 
2006 (2) 
Dying people eligible for anti-
emetic studies 
# I: Cluster consent B 
C: Zelen consent+  C 
Yes (cluster consent) 
Improving trial 
information for 
individual participants  
Coyne 2003 (1) 
Cancer treatment trial 
population 
I: Easy-to-read consent 
C: Usual consent process 
No 
Hutchison  
2007 (3) 
I: Audio-visual information 
about clinical trials 
C: Usual consent process 
No**  C 
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Junghans 2005 
(5) 
People with angina 
# I: Opt-in  
C: Opt-out 
Yes^^ D 
Du 2008 (3) People with lung cancer I: Clinical trial video 
C: Usual consent process 
No 
Du 2009 (2) People with breast cancer No 
Hunt 2013 Bereaved relatives ## 
# I: Opt-in  
C: Opt-out 
Yes^^ D 
Pighills 
2009 
People at risk of falls >70yo 
## 
I: Newspaper article 
C: Usual consent process 
No 
 
Potential participants 
requiring emergency 
treatment  
Leira 2009 (3) 
 
People having had a stroke 
awaiting medi-evac to a major 
center 
 
# I: Study information and 
contact with researcher while 
awaiting transfer 
C: Contact on arrival at tertiary 
treatment center 
 
Yes 
 
S
I
T
E
-
R
E
L
A
T
E
D
 
S
T
U
D
I
E
S
 
Improving trial 
information for trial sites  
Kimmick 2005 
(1) 
CALGB^ sites 
I: Addition of educational 
seminar  
C: Usual web access and 
periodic reminders 
No 
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Lienard 
2006 (2) 
Sites recruiting to a 
chemotherapy study 
I: Face-to-face visits for site 
initiation  
C: No visits 
No 
Monaghan  
2007 (2) 
Sites recruiting to diabetes 
and vascular disease 
interventions 
I: Tailored feedback to sites 
about recruitment performance 
C: Usual process 
No 
a Significantly reduced entry to appropriate clinical trials as a result. 
** When adjusted for cancer stage and ethnicity, there was significantly increased recruitment 
B# Evaluated a control group unless noted  
## Quasi-experimental design 
^ Cancer and Leukaemia Group B  
^^ Opt-out favoured over opt-in 
C+ Zelen consent – participant consent after randomisation 
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Table 5. Full-Text Articles Excluded, with Reasons 
 
Article  Reason for Exclusion 
Abbott 2005 (54) Not assessing a recruitment methodology 
Abboud 2006 (55) Hypothetical trial 
Avenell 2004 (56) Wrong patient group 
Beckie 2009 (48) Wrong trial design  
Bentley 2004 (57) Hypothetical trial 
Brandt 2006 (58) Not assessing a recruitment methodology 
Chang 2004 (59) Not assessing a recruitment methodology  
Chen 2005 (60) Not assessing a recruitment methodology 
Couper 2008 (61) Not assessing a recruitment methodology 
68De Boer 2011  (62) Wrong trial design 
Diguiseppi 2006 (63) Hypothetical trial 
Edland 2010 (64) Not assessing a recruitment methodology 
Ellis 2002 (65) Hypothetical trial 
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Ferris 2006, (66) Not assessing a recruitment methodology 
Flaherty 2008 (67) Wrong trial design 
Ford 2004 (68) Wrong patient group 
Freer 2009 (69) Wrong patient group 
Gallagher-Thompson 2004 (70) Wrong trial design 
Graham 2007 (71) Wrong patient group 
Halpern 2004 (72) Hypothetical trial 
Hanratty 2012 (53) Wrong patient group 
Harris 2008 (73) Wrong patient group 
Hemminki E 2004 (74) Wrong patient group 
Howard 2006 (75) Wrong trial design 
Irwin 2008 (49) Not assessing a recruitment methodology  
Jeste 2009 (76) Hypothetical trial 
Kaas 2005 (77) Wrong trial design 
karlawish 2008 (78) Not assessing a recruitment methodology 
karunaratne 2010 (79) Hypothetical trial 
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Kennedy 2011 (80) Wrong patient group 
Kerr 2004 (81) Hypothetical trial 
Kye 2009 (82) Wrong trial design 
Larkey 2002 (83) Wrong patient group 
Leathem 2009 (84) Not assessing a recruitment methodology 
Mangset 2008 (85) Not assessing a recruitment methodology 
Melchart 2002 (86) Not assessing a recruitment methodology 
Mount 2012 (87) Not assessing a recruitment methodology 
Nystuen 2004 (88) Wrong patient group  
Pearl 2003 (89) Not assessing a recruitment methodology 
Rees 2003 (43) Wrong trial design 
Sano 2010 (90) Not assessing a recruitment methodology 
Serfaty 2012 (91) Not assessing a recruitment methodology 
Sisk 2008 (92) Not assessing a recruitment methodology 
Stone 2013 (51) Wrong trial design 
Switzer 2010 (45) Wrong trial design 
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Treschan 2003 (93) Wrong patient group 
Trevena 2006 (94) Wrong patient group 
Tworoger 2002 (95) Wrong patient group 
Warner 2008 (96) Wrong trial design 
Webb 2009 (97) Wrong patient group  
Weinfurt 2008 (98) Hypothetical study 
Whitehouse 2006 (99) Wrong patient group 
Williams 2005 (100) Not assessing a recruitment methodology 
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Appendix 
Study Design/Conduct Aspects Addressed by Recruitment Strategies 
Data Extraction Form 
Article details: 
What was the research question? 
hypothesis 
 
P) Description of patient population in study 
Study population: 
Number of subjects:  
Age range: 
Gender: 
PS description: 
Method of recruitment: 
Other ________________________ 
I) What is the intervention? ________________________________________________ 
C) Comparator: _________________________________________________________  
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O) Outcome 
Primary 
Secondary 
Was it effective? Yes/no 
Measure of effectiveness (e.g., in results or said what they measured – total recruitment, finished study on time): 
Study design 
RCT 
Quasi experimental study 
Observation Cohort (stat what retro/prospective/Before and after study) 
Substudy of an RCT 
Post hoc opinion (we did this and thought this helped) 
Other ……………………… 
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Table 4A. Included trials (ONLINE ONLY) 
Strategies to Address the Challenge of Potential Participants with Reduced Cognitive Ability 
Study, Design 
and Quality of 
Evidence (Jadad 
score for RCTs) 
 
Patient Population Intervention and 
Comparator 
Outcome Effect on recruitment 
Rubright 2010 
(19) 
RCT  
 Jadad 3 
 
Group 1: people with AD  
N=40; MMSE 18–27  
Age: mean (range):  74 
(45 to 92)  
Gender: 43% Female  
 
Group 2: people with AD 
N=40; MMSE 18–27  
Age: 77 (59–89) 
Intervention (group 1): 
Standard consent plus a 
memory and organizational aid  
 
Comparator 1 (group 2): 
standard consent  
 
Comparator 2 (group 3): 
standard consent 
Primary outcome: 
AD participants 
assessed as 
competent to provide 
their own consent  
 
Secondary outcome : 
effect on decision 
making abilities  
Increased number of 
consented participants 
assessed as competent and 
able to provide their own 
consent 
  
Group 1: n=19 
Group 2: n=7  
P= 0.004 
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Gender: 58% Female  
 
Group 3: Cognitively 
normal older adults 
N= 30; MMSE 28–30  
Age, mean (SD): 78 (60–
89) 
Gender: 57% Female 
Adamis 2005 
(28) 
RCT  
Jadad 3 
 
Unwell hospital medical 
inpatients over 70 years 
within 3 days of an acute 
admission  
N=130  
Age, mean (SD): 84 (SD 
6.5) 
Gender: 56% female 
Intervention: Two step 
procedure. Formal assessment 
of mental capacity prior to 
informed consent procedure 
 
Comparator:  Single step 
procedure. Usual practice 
(informal assessment of mental 
Primary outcome: 
Consented patients  
 
Secondary outcome: 
representativeness of 
sample 
Primary outcome 
Recruitment: 
Intervention: 44%  
Comparator: 74%  
 
Secondary outcome:  
Assessed as having capacity 
Intervention: 60%  
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capacity during informed 
consent procedure)  
Comparator: 86%  P=0.001 
 
Participants discharged to a 
nursing home: 
Intervention: 5% 
Comparator: 28.6%  P=0.03 
Lower severity of delirium 
in intervention group 
Stocking 2007 
(27) 
RCT 
Jadad 2 
 
Patients with AD and 
their family proxies  
 N=149 
MMSE 2-29. 
Age, median (range): 
78.6 (52 to 94)  
Gender: 62% Female 
Intervention: Planning Ahead 
Together (PAT) document 
(research advance directive) 
 
Comparator: usual practice 
Recruitment into 
research projects over 
2 years 
 
Ease of decision of 
enrolment  
41 patients invited to 
participate in a study (23 
PAT, 18 no PAT) 
27 consented  
No difference between 
groups for either outcome 
(patients or proxies; PAT or 
no PAT) 
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Fowell 2006 
(25) 
Feasibility  
Cluster vs 
patient consent 
crossover RCT  
Jadad 2  
Eligible cancer patients 
admitted to 1 oncology 
ward and 1 palliative care 
unit in the context of a 
trial of anti-emetics in 
dying patients 
 
Group 1: patients dying 
during the cluster design 
phases 
N = 24 
Gender: 58% male 
Group 2: patients dying 
during the Zelen consent 
phase 
N = 29 
Group 1: cluster consent * 
Group 2: Zelen** consent 
 
* - cluster guardian and cluster 
gatekeeper obtained consent 
from  eligible patient 
** patient consent after 
randomisation to trial 
intervention 
i) Patients consenting 
ii) Patients 
randomised 
i) Patients consenting 
group 1: 13 
group 2: 2 
ii) Patients randomised 
group 1; 6 
group 2: 0 
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Gender: 59% male 
Strategies to Address the Challenge of Potential Participants Requiring Emergency Treatment 
Study/ Design Patient Population Intervention and 
Comparator 
Outcome Effect on recruitment 
Leira 2009 
(29) 
RCT 
Jadad 3 
 
 
Consecutive patients/or 
surrogates presenting 
with stroke to a 
community hospital ED 
awaiting helicopter 
transfer to tertiary centre.  
N= 100  
Age, mean (SD): 63.9 
(13.3)  
Gender: 56% male  
Intervention: 1) faxed study 
information to 
patient/surrogate whilst 
awaiting helicopter arrival 
2) telephone call from the co-
investigator to the 
patient/surrogate from the 
helicopter whilst en-route. 
Comparator: patient/surrogate 
approached with study 
Consent rate in group 
receiving pre-arrival 
fax and telephone call 
Intention to treat;  
Consent rate:  
Intervention group: 54% 
control group: 50% 
p=0.69 
 
Per-protocol analysis (When 
faxed information and 
telephone call were both 
successfully achieved) 
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information on arrival at the 
tertiary hospital 
Consent rate 69% 
P=0.04 
Strategies  to Improve Trial Information and Research Willingness to 1) Potential Participant 
Study/ Design Patient Population Intervention and 
Comparator 
Outcome Effect on recruitment 
Coyne 2003 
(20) 
Cluster RCT 
of 44 institutions 
across 3 
oncology 
collaboratives 
Jadad 1 
Cancer patients eligible 
to participate in cancer 
treatment trials  
Group 1) standard 
consent 
N =137 
Age (mean): 53 
Gender: male 9.3% 
Group 2) easy to read 
consent 
N =89 
Group 1: standard consent 
information   
Group 2: easy to read consent 
information 
 
Accrual rates 
 
Participant anxiety 
and satisfaction re 
consent information 
Decision to participate 
(actual accrual) 
Group 1: 89%; (68%) 
Group 2: 82%; (75%)    P = 
0.21; (P = 0.32) 
 
Consent anxiety 
Group 1: 2.1 
Group 2: 1.8    P = 0.016 
Consent satisfaction 
Group 1: 3.3 
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Age (mean): 53 
Gender: male 7.3% 
Group 2: 3.6    P = 0.004 
Junghans 2005 
(31) 
RCT 
Jadad 5 
Patients in primary care 
with angina 
N= 510 
Group 1: N = 252 
Group 2: N = 258 
 
Group 1: opt in approach to 
recruitment into an 
observational trial 
Group 2: opt out approach to 
recruitment into an 
observational trial 
Recruitment rate 
 
Patient characteristics 
Group 1: 38% (96/252) 
Group 2: 50% (128/258) 
P = 0.014 
 
Participants in group 1 had 
fewer risk factors (P = 
0.053), less treatment for 
angina (P = 0.01) and less 
functional impairment (P = 
0.023) than group 2 
 
Du 2008 
(22) 
RCT 
Lung cancer patients 
Group1) 
N = 63 
Group 1: view 18 minute video 
about clinical trials before first 
oncology clinic visit 
Enrolment rates for i) 
therapeutic trials; ii) 
therapeutic and non-
Enrolment 
i) therapeutic trials 
group 1:17.5% 
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Jadad 3 Age (mean) = 58.2 
Gender = 49% male 
Group 2) 
N = 63 
Age (mean) = 58.7 
Gender = 52% male 
Group 2: usual care therapeutics trials group 2: 11.1%    P = 0.3 
 
ii) non-therapeutic and 
therapeutic trials 
group 1: 24.5% 
group 2: 15.9%    P = 0.19 
Du 2009 
(23) 
RCT 
Jadad 2 
Breast cancer patients 
 
N = 196  
Ethnicity: 55% white; 
45% African American 
Gender: 0% male 
Group 1: view 18 minute video 
about clinical trials before first 
oncology clinic visit 
 
Group 2: usual care 
 
Stratified by race: White or 
African American women 
Enrolment rates for i) 
therapeutic trials; ii) 
effect of race 
 
Attitude (likelihood 
of entering trial if 
offered) 
 
 
Enrolment 
i) therapeutic trials 
group 1:10.4% vs group 2: 
6.1%    P = 0.3 
ii) effect of race 
white 11.2%  vs black 4.5%  
P = 0.087 
when adjusted for stage of 
disease P = 0.049 
Attitude – “extremely likely 
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to enrol” 
white 23%  vs black 12%  P 
= 0.05 
no “improvement” in AA 
attitude in follow up in seen 
video  vs those who had not 
Pighills 2009 
(33) 
Two quasi- 
controlled trials 
 
Potential participants for 
a falls prevention study in 
primary care (age >70) 
 
Study 1. 
N = 4488 
Study 2. 
N = 2745 
Study 1. 
Group 1: newspaper article 
about the study + participant 
information 
Group 2: participant 
information only 
Study 2. 
Group 1: favourable 
newspaper article about the 
study + participant information 
Recruitment rate Percentage enrolled 
Study 1. 
Group 1: 3.25% 
Group 2: 3.16%    NS 
 
Study 2. 
Group 1: 4.15% 
Group 2: 3.94%     NS 
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Group 2: participant 
information only 
Hutchison 2007 
(21) 
RCT 
Jadad 3 
Cancer patients eligible 
for entry into a cancer 
therapeutic trial 
Group 1: 
N  = 86 
Gender: 23.3% male 
Group 2: 
N = 87 
Gender:23 % male 
Group 1: audiovisual patient 
information + standard trial 
specific information 
Group 2: standard trial specific 
information 
Recruitment rate 
 
 
Recruitment rate 
 
Group 1:72.1% 
Group 2: 75.9%     
OR 1.19 (95% CIs 0.55 – 
2.58) p = 0.661 
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Hunt 2013 
(30) 
Quasi-
experimental 
(alternate 
numbers 
allocated to 
different groups) 
 
Bereaved relatives 
contacted to take part in a 
survey 
N = 1422 
Group 1: opt in – had to send 
to get survey in response to 
invitation 
Group 2: opt out – survey 
included in invitation letter 
Response rate to 
survey 
 
Distress caused by 
survey 
Response 
Overall response; 473/1422 
(33%)  
Group 1: 188/ 711 (26.4%) 
Group 2: 285/711 (40%) 
P < 0.01 
 
No difference in distress 
Strategies  to Improve Trial Information and Research Willingness to 2) Potential Recruiting Sites 
Study/ Design Patient Population Intervention and 
Comparator 
Outcome Effect on recruitment 
Kimmick 2005 
(26) 
Cluster RCT 
Jadad 1 
Member institutions of 
the Cancer and 
Leukaemia group B 
Group 1: institutions  
Group 1: standard = website 
access and periodic 
notification of trials 
Group 2: standard  + 
Proportion of older 
(>65)  cancer patient 
accrual to trials at 
baseline, 1 year and 2 
Baseline proportion of >65 
recruited:  
Group 1: 36% 
Group 2: 40%  P = 0.4 
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receive standard 
information about trials 
N = 72 institutions 
Group 2: institutions 
receive standard plus 
educational intervention 
N = 53 institutions 
educational seminar and 
materials + list of protocols + 
monthly reminders + case 
discussion seminar 
year  
One year 
Group 1: 32% 
Group 2: 36%  P = 0.35 
 
Two year 
Group 1: 31% 
Group 2: 31% P = 0.83 
Lienard 2006 
(24) 
Cluster RCT 
Jadad 2 
Sites recruiting to an 
RCT comparing two 
types of chemotherapy 
for cancer 
Group 1: 68 sites 
Group 2: 67 sites 
Group 1: systematic face to 
face site visits for study 
initiation 
Group 2: not visited 
Recruitment rate per 
site 
Number of patients recruited 
Group 1: Total 302 patients 
- Poor recruiting sites 11 
- Average recruiting sites 
48 
- Good recruiting sites 36 
- Excellent recruiting sites 
207 
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Group 2: Total 271 patients 
- Poor 11 
- Average 42 
- Good 70 
- Excellent 148 
Monaghan 2007 
(32) 
Cluster RCT 
Jadad 2 
Clinical centres recruiting 
to an RCT for diabetes 
and vascular disease 
intervention 
Group 1:  
N = 85 
Group 2:  
N = 82 
Group 1: additional 
communication strategies from 
trial co-ordinating unit 
(individual tailored feedback 
about recruitment rate using 
email, updates, certificates) 
Group 2: usual communication 
strategies (occasional generic 
newsletters, emails and faxes) 
Recruitment rate per 
centre 
Median number of patients 
randomised by centre 
Group 1: 37.5 patients 
Group 2: 37 patients 
P = 0.68 
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Figure Legend 
Fig. 1. PRISMA flow diagram. 
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Figure 1: PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching (n = 627) 
Sc
re
en
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources (n = 48) 
Records after duplicates removed 
(n =549) 
Records screened 
(n = 549) 
Records excluded 
(n = 481) 
Full-text articles assessed 
for eligibility (n = 68) 
Full-text articles excluded 
with explanation (n = 53) 
Table 2 
Studies included in qualitative 
synthesis (n = 15) 
 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = N/A) 
